Rapalink-1, the new drug studied by the team, is a next-generation TOR inhibitor currently under investigation for cancer therapy. The researchers found that rapalink-1 not only slowed aspects of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback